Section Arrow
ONCO.NASDAQ
- Onconetix Inc.
Quotes are at least 15-min delayed:2026/09/04 00:35 EDT
Regular Hours
Last
 0.739
+0.0647 (+9.60%)
Day High 
0.7445 
Prev. Close
0.6743 
1-M High
1.009 
Volume 
289.13K 
Bid
0.71
Ask
0.7399
Day Low
0.6601 
Open
0.6818 
1-M Low
0.5868 
Market Cap 
2.66M 
Currency 美元 
P/E
%Yield -- 
10-SMA 0.65 
20-SMA 0.75 
50-SMA 0.84 
52-W High 209.5 
52-W Low 0.5868 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
749.08/-1.18
Enterprise Value
2.69M
Balance Sheet
Book Value Per Share
3.41
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
815.37K
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
RAREUltragenyx Pharmaceutical14.85-11.68-44.03%-- 
AIMAIM ImmunoTech Inc.0.2337-0.0009-0.38%-- 
ATAIAtaiBeckley Inc7.34-0.01-0.14%-- 
SMMTSummit Therapeutics17.13+2.53+17.33%-- 
IOVAIovance Biotherapeutics8.7+0.08+0.93%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.